{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.92","upperLimit":"1.02","value":"0.97"},{"groupId":"OG001","lowerLimit":"1.12","upperLimit":"1.12","value":"1.12"},{"groupId":"OG002","lowerLimit":"1.00","upperLimit":"1.25","value":"1.09"},{"groupId":"OG003","lowerLimit":"1.09","upperLimit":"1.09","value":"1.09"},{"groupId":"OG004","lowerLimit":"1.09","upperLimit":"1.25","value":"1.15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"description":"Tmax for TAK-981 was reported.","dispersionType":"Full Range","groups":[{"description":"Participants received TAK-981 60 mg, infusion, intravenously, twice weekly on Days 1, 4, 8, 11 and 15, and mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15 and 22 during Cycles 1 and 2, then once every 2 weeks during Cycles 3 through 6, further once every 4 weeks, until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG000","title":"Phase 1b, Part 1: TAK-981 60 mg BIW + Mezagitamab 600 mg"},{"description":"Participants received TAK-981 90 mg, infusion, intravenously, twice weekly on Days 1, 4, 8, 11 and 15, and mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15 and 22 during Cycles 1 and 2, then once every 2 weeks during Cycles 3 through 6, further once every 4 weeks, until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG001","title":"Phase 1b, Part 1: TAK-981 90 mg BIW + Mezagitamab 600 mg"},{"description":"Participants received TAK-981 90 mg, infusion, intravenously, in combination with mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15, 22 during Cycles 1 and 2, then every 2 weeks during Cycles 3 through 6, further once every 4 weeks until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG002","title":"Phase 1b, Part 1: TAK-981 90 mg QW + Mezagitamab 600 mg"},{"description":"Participants received TAK-981 120 mg, infusion, intravenously, twice weekly on Days 1, 4, 8, 11 and 15, and mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15 and 22 during Cycles 1 and 2, then once every 2 weeks during Cycles 3 through 6, further once every 4 weeks, until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG003","title":"Phase 1b, Part 1: TAK-981 120 mg BIW + Mezagitamab 600 mg"},{"description":"Participants received TAK-981 120 mg, infusion, intravenously, in combination with mezagitamab 600 mg, injection, subcutaneously, once weekly on Days 1, 8, 15, 22 during Cycles 1 and 2, then every 2 weeks during Cycles 3 through 6, further once every 4 weeks until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG004","title":"Phase 1b, Part 1: TAK-981 120 mg QW + Mezagitamab 600 mg"}],"paramType":"MEDIAN","populationDescription":"PK analysis set included participants with sufficient dosing and PK data to reliably estimate 1 or more PK parameters. Here \"overall number of participants analyzed\" signifies participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: pre-dose and at multiple timepoints (up to 24 hours) post-dose (Cycle length = 28 days)","title":"Phase 1b, Part 1, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-981","type":"SECONDARY","unitOfMeasure":"hours"}